Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rallybio ( (RLYB) ) has shared an update.
Rallybio Corporation announced that on February 24, 2025, it received a notification from Nasdaq regarding its non-compliance with the minimum closing bid price requirement of $1.00 per share over the past 30 consecutive business days. Despite not meeting the requirement by the initial compliance date of August 25, 2025, Nasdaq approved Rallybio’s application to transfer its listing to the Nasdaq Capital Market, granting an additional 180 days until February 23, 2026, to regain compliance. Rallybio plans to monitor its stock price and consider options such as a reverse stock split to meet the requirement, with potential delisting consequences if compliance is not achieved.
The most recent analyst rating on (RLYB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Rallybio stock, see the RLYB Stock Forecast page.
Spark’s Take on RLYB Stock
According to Spark, TipRanks’ AI Analyst, RLYB is a Underperform.
Rallybio’s stock is under significant pressure due to poor financial performance characterized by operational losses and negative cash flows, compounded by bearish technical indicators and challenging valuation metrics. Without revenue growth, the sustainability of operations is at risk, making it a highly speculative investment in its current state.
To see Spark’s full report on RLYB stock, click here.
More about Rallybio
Average Trading Volume: 2,918,865
Technical Sentiment Signal: Sell
Current Market Cap: $23.41M
Find detailed analytics on RLYB stock on TipRanks’ Stock Analysis page.